【Portfolio News】安济药业对外公开两个关键项目进展
Jun 24, 2022
【Portfolio News】Anji Pharma Provides Update on Two Lead Programs
Jun 23, 2022
【Portfolio News】维亚生物程学恒博士:大分子VS小分子,小分子新药发现技术或是突破的关键
Jun 19, 2022
【Portfolio News】安济药业完成ANJ900中国桥接研究
Jun 15, 2022
【Portfolio News】Viva Biotech 2022 Partnership Summit June 16th to 20th
Jun 14, 2022
【Portfolio News】Anji Pharma Provides Update on ANJ900 Pivotal Program
Jun 2, 2022
May 31, 2022
【Portfolio News】VIVA朋友圈丨启愈生物将于2022年ASCO年会上公布其Q-1802的最新临床数据
May 31, 2022
【Portfolio News】Viva Biotech Announced New Website and Logo
May 23, 2022
【Portfolio News】安济药业顺利完成ANJ908全球2期临床试验入组
May 20, 2022
【Portfolio News】维眸生物同泰槿生物宣布战略合作关系,助力开发眼底疾病相关的抗体药
May 18, 2022
【Portfolio News】维眸生物宣布同Maculus达成战略合作,加速推进眼底药物研发进程
May 13, 2022
【Portfolio News】SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
May 10, 2022
【Portfolio News】Julianne Averill and Kristen Richardson Join Anji Pharma to Ready Company for Next Stage of Growth
May 4, 2022
【Portfolio News】维眸生物干眼症创新药VVN001美国II期临床试验结果积极
March 23, 2022
【Portfolio News】维眸生物与合全药业签署战略合作协议 加快眼科创新药开发进程
Dec 30, 2021
【Portfolio News】维眸生物招募首位受试者入组VVN001中国II期临床试验
Dec 10, 2021
【Portfolio News】维眸生物宣布成立科学顾问委员会并召开首次科学顾问委员会会议及专家研讨会
Dec 1, 2021
【Portfolio News】Anji Pharma Fully Enrolls Cohort at Leading Beijing Hospital to Ready Global ANJ900 Pivotal Program in Asia
Nov 30, 2021
Nov 29, 2021
Oct 15, 2021
【Portfolio News】维眸生物签约临港新片区:正式启动产业化布局
Oct 14, 2021
【Portfolio News】Anji Pharma Secures $70 Million to Deploy Dynamic Equity and Further Build a Global Medicines Company
Sep 28, 2021
Sept 1, 2021
【Portfolio News】维眸生物招募第一位受试者入组VVN001中国临床I期试验
Aug 26, 2021
June 17, 2021
【Portfolio News】Anji Pharma Launches Phase 3 Trial for ANJ900 to Treat Type 2 Diabetes Patients with Kidney Disease
June 10, 2021
【Portfolio News】维眸生物完成3亿元融资,红杉中国领投,岱岱资本(Viva Ventures)加注
April 19, 2021
【Portfolio News】Anji Pharma Acquires Global Development Rights for ApoE Mimetic Peptides from LipimetiX
Feb 18, 2021
【Portfolio News】维眸生物任命李晓燕博士担任首席医学官
Jan 15, 2021
【Portfolio News】维眸生物:干眼症新药VVN001美国临床II期研究完成首例患者入组
Dec 18, 2020
【Portfolio News】维眸与贝达基金共建免疫创新药公司,启元生物正式启航
Dec 10, 2020
【Portfolio News】Arthrosi Therapeutics Released Phase 2 Clinical Data of AR882, Considerably Outperformed the Current Frontline Therapies
November 7, 2020
【Portfolio News】突破高难度靶点,维眸生物以独创能力加码眼疾创新药研发疾创新药研发
October 28, 2020
【Portfolio News】Dogma Therapeutics Announces Global Acquisition of Oral PCSK9 Inhibitor Program by AstraZeneca
September 17, 2020
【Portfolio News】维眸生物新一代LFA1抑制剂VVN001递交美国临床II期试验申请
September 2, 2020
【Portfolio News】专访|维眸生物创始人沈旺:中国创新药政策红利还将保持5至10年
May 27, 2020
May 27, 2020
【Portfolio News】SQZ Biotech Announces First Patient Dosed in Phase 1 Trial
January 30, 2020
【Portfolio News】维亚生物荣获动脉澎橙奖
December 23, 2019
【Portfolio News】Anji Pharma Secures China Rights to Apo E Mimetic Platform from LipimetiX Development
May 7, 2018
【Portfolio News】Anji Pharma Launches a Global Strategy to Accelerate Medicines to China and Other Markets
May 1, 2018